Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal

Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin